Lion Point Capital’s Innate Pharma IPHA Stock Holding History

Lion Point Capital’s Portfolio IPHA Stock Details IPHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$104K	Hold	81,151	–	–	0.62%	34
2025 Q4	$142K	Buy	+81,151	New	+$157K	0.73%	35

Other funds holding IPHA

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $541M AUM 1,009.51% 1-Year Est. Return

Lion Point Capital's IPHA Position: Q1 2026 in Review

Lion Point Capital held its Innate Pharma (IPHA) position steady in Q1 2026 at 81,151 shares worth $104K. The position accounts for 0.62% of the portfolio, ranked #34.

Lion Point Capital first reported a position in IPHA in Q4 2025 and has held it in 2 quarters since. The position peaked at $142K in Q4 2025. 9 funds tracked by Wall St. Rank hold IPHA as of Q1 2026.

Lion Point Capital held 81,151 shares of Innate Pharma worth $104K as of Q1 2026.
Lion Point Capital left its Innate Pharma share count unchanged in Q1 2026.
Innate Pharma made up 0.62% of Lion Point Capital's portfolio in Q1 2026, its #34 holding.
Lion Point Capital first reported a position in Innate Pharma in Q4 2025 and has held it in 2 quarters since.
Lion Point Capital's Innate Pharma position peaked at $142K in Q4 2025.
9 funds tracked by Wall St. Rank held Innate Pharma as of Q1 2026.

Based on Lion Point Capital's 13F filing for Q1 2026, filed 15 May 2026.